Needham & Company LLC Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $72.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price target reduced by Needham & Company LLC from $108.00 to $72.00 in a research report report published on Thursday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. CYTK has been the subject of several other research reports. JMP Securities lowered their price […]

Related Keywords

, Johnt Henderson , Fady Ibraham Malik , Victory Capital Management Inc , Vanguard Group Inc , Securities Exchange Commission , Legato Capital Management , Cytokinetics Company Profile , Needham Company , Cytokinetics Incorporated , Free Report , Moderate Buy , Get Free Report , Ibraham Malik , Exchange Commission , Director John , Minvest Partners , Capital Management , Victory Capital Management , Cytokinetics Daily ,